C3aR and C5aR Antibody Modulation for Cell Growth Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively modulate growth factor responses in cells expressing C3a and C5a receptors, leading to uncontrolled cell growth and proliferation in conditions such as neointimal formation, atherosclerosis, and cancer, where inhibiting or promoting growth factor signaling is desired.
Innovation Solution
Administering agents that modulate C3aR and C5aR signaling, such as complement antagonists, STAT3/IL-6 signaling pathway antagonists, and thrombin inhibitors, to cells expressing these receptors, particularly in vascular tissues and cancer cells, to inhibit or promote growth, viability, and mitosis in response to growth factor stimulation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If growth factor signaling is left unmodulated, then cell growth and proliferation proceed naturally, but uncontrolled cell growth leads to pathological conditions such as neointimal formation, atherosclerosis, and cancer
Solution Approach 1:
The patent uses C3aR and C5aR receptors as intermediary targets to modulate growth factor signaling. By administering complement antagonists that bind to C3aR or C5aR, the invention creates an indirect control mechanism that regulates downstream growth factor responses (VEGF, PDGF, EGF) without directly targeting the growth factor pathways themselves, thereby achieving reliable control over cell growth while avoiding the harmful effects of uncontrolled proliferation
Solution Approach 2:
The invention changes the signaling parameters of complement receptors C3aR and C5aR through pharmacological modulation. By administering complement antagonists that alter the activation state of these receptors, the patent effectively changes the downstream signaling parameters of growth factor pathways, converting an uncontrolled biological process into a regulated one that can be therapeutically managed
2Object-affected harmful factors
If complement antagonists are administered to inhibit C3aR and C5aR signaling, then cell growth and proliferation are inhibited in pathological conditions, but the ability to promote tissue repair and angiogenesis must be maintained
Solution Approach 1:
The patent applies local quality by targeting specific cell types and tissue contexts. Complement antagonists are designed to inhibit C3aR and C5aR signaling in pathological tissues (such as atherosclerotic plaques, neointimal lesions, or tumors) while preserving normal physiological functions in healthy tissues. This selective modulation allows inhibition of harmful proliferation in diseased areas while maintaining tissue repair and angiogenesis capabilities in regenerating tissues
Solution Approach 2:
The invention employs dynamic modulation of complement receptor signaling rather than complete blockade. By administering complement antagonists at controlled doses and timing, the patent creates a dynamic system that can adapt its level of inhibition based on physiological needs, allowing suppression of pathological proliferation when needed while permitting tissue repair processes to proceed when appropriate
Data Source
AI summary
A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells.